About Editas Medicine
Industry:
Gene Editing/Biotechnology
Founded:
2013
Founders:
Feng Zhang, Jennifer Doudna, George Church, David Liu, Keith Joung
Status:
Public (NASDAQ: EDIT)
Funding & Growth
Total Raised:
$700M+
Valuation:
$500M+ market cap
Stage:
Public
Key Investors:
Google Ventures
Boris Nikolic
Polaris Partners
✓ Pros
- • Founded by CRISPR pioneers
- • Strong scientific pedigree
- • Cambridge biotech ecosystem
- • Focus on genetic diseases
- • Collaborative culture
✗ Cons
- • Smaller company resources
- • Stock volatility
- • Competitive landscape
- • Clinical stage risks